Effective second-line chemotherapy for extranodal NK/T-cell lymphoma consisting of etoposide, ifosfamide, methotrexate, and prednisolone

Byung Soo Kim, D. W. Kim, S. A. Im, C. W. Kim, T. Y. Kim, S. S. Yoon, D. S. Heo, Y. J. Bang, S. Park, B. K. Kim, N. K. Kim

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Background: Many patients with extranodal natural killer/T-cell lymphoma (NTCL) fail to the front-line therapy and need an effective second-line chemotherapy. Patients and methods: This was single-institutional, phase II study. The primary end point was response rate and secondary end points were toxicity, time to treatment failure (TTF), and overall survival (OS). Patients with relapsed or refractory NTCL were eligible. They received the chemotherapy consisting of ifosfamide, methotrexate, etoposide, and prednisolone and it was repeated every 3 weeks. Results: Thirty-two patients were enrolled and 15 patients had achieved partial remission (PR) or complete remission (CR) after the front-line chemotherapy. The International Prognostic Index scores were 0-1 in thirteen, 2 in five, 3 in five, and 4-5 in nine patients. Twelve and two patients achieved CR and PR, respectively. Median OS and TTF of all patients were 8.2 and 3.7 months, respectively. Non-hematologic toxic effects were well tolerated, but grade 3/4 leukopenia occurred in 11.7% of all cycles. Four patients developed febrile neutropenia and one patient died due to pneumonia. Conclusions: This chemotherapy regimen was moderately effective for relapsed/refractory extranodal NTCL, nasal type. Toxic effects were moderate, but caution should be exercised to prevent severe infection.

Original languageEnglish
Pages (from-to)121-128
Number of pages8
JournalAnnals of Oncology
Volume20
Issue number1
DOIs
Publication statusPublished - 2009 Feb 3
Externally publishedYes

Fingerprint

Extranodal NK-T-Cell Lymphoma
Ifosfamide
Etoposide
Prednisolone
Methotrexate
Drug Therapy
Natural Killer T-Cells
T-Cell Lymphoma
Poisons
Treatment Failure
Febrile Neutropenia
Survival
Leukopenia
Nose

Keywords

  • NK/T-cell lymphoma
  • Salvage chemotherapy
  • Second-line chemotherapy

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Effective second-line chemotherapy for extranodal NK/T-cell lymphoma consisting of etoposide, ifosfamide, methotrexate, and prednisolone. / Kim, Byung Soo; Kim, D. W.; Im, S. A.; Kim, C. W.; Kim, T. Y.; Yoon, S. S.; Heo, D. S.; Bang, Y. J.; Park, S.; Kim, B. K.; Kim, N. K.

In: Annals of Oncology, Vol. 20, No. 1, 03.02.2009, p. 121-128.

Research output: Contribution to journalArticle

Kim, BS, Kim, DW, Im, SA, Kim, CW, Kim, TY, Yoon, SS, Heo, DS, Bang, YJ, Park, S, Kim, BK & Kim, NK 2009, 'Effective second-line chemotherapy for extranodal NK/T-cell lymphoma consisting of etoposide, ifosfamide, methotrexate, and prednisolone', Annals of Oncology, vol. 20, no. 1, pp. 121-128. https://doi.org/10.1093/annonc/mdn551
Kim, Byung Soo ; Kim, D. W. ; Im, S. A. ; Kim, C. W. ; Kim, T. Y. ; Yoon, S. S. ; Heo, D. S. ; Bang, Y. J. ; Park, S. ; Kim, B. K. ; Kim, N. K. / Effective second-line chemotherapy for extranodal NK/T-cell lymphoma consisting of etoposide, ifosfamide, methotrexate, and prednisolone. In: Annals of Oncology. 2009 ; Vol. 20, No. 1. pp. 121-128.
@article{aae4a1709259464f83f81a6513f6fb24,
title = "Effective second-line chemotherapy for extranodal NK/T-cell lymphoma consisting of etoposide, ifosfamide, methotrexate, and prednisolone",
abstract = "Background: Many patients with extranodal natural killer/T-cell lymphoma (NTCL) fail to the front-line therapy and need an effective second-line chemotherapy. Patients and methods: This was single-institutional, phase II study. The primary end point was response rate and secondary end points were toxicity, time to treatment failure (TTF), and overall survival (OS). Patients with relapsed or refractory NTCL were eligible. They received the chemotherapy consisting of ifosfamide, methotrexate, etoposide, and prednisolone and it was repeated every 3 weeks. Results: Thirty-two patients were enrolled and 15 patients had achieved partial remission (PR) or complete remission (CR) after the front-line chemotherapy. The International Prognostic Index scores were 0-1 in thirteen, 2 in five, 3 in five, and 4-5 in nine patients. Twelve and two patients achieved CR and PR, respectively. Median OS and TTF of all patients were 8.2 and 3.7 months, respectively. Non-hematologic toxic effects were well tolerated, but grade 3/4 leukopenia occurred in 11.7{\%} of all cycles. Four patients developed febrile neutropenia and one patient died due to pneumonia. Conclusions: This chemotherapy regimen was moderately effective for relapsed/refractory extranodal NTCL, nasal type. Toxic effects were moderate, but caution should be exercised to prevent severe infection.",
keywords = "NK/T-cell lymphoma, Salvage chemotherapy, Second-line chemotherapy",
author = "Kim, {Byung Soo} and Kim, {D. W.} and Im, {S. A.} and Kim, {C. W.} and Kim, {T. Y.} and Yoon, {S. S.} and Heo, {D. S.} and Bang, {Y. J.} and S. Park and Kim, {B. K.} and Kim, {N. K.}",
year = "2009",
month = "2",
day = "3",
doi = "10.1093/annonc/mdn551",
language = "English",
volume = "20",
pages = "121--128",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Effective second-line chemotherapy for extranodal NK/T-cell lymphoma consisting of etoposide, ifosfamide, methotrexate, and prednisolone

AU - Kim, Byung Soo

AU - Kim, D. W.

AU - Im, S. A.

AU - Kim, C. W.

AU - Kim, T. Y.

AU - Yoon, S. S.

AU - Heo, D. S.

AU - Bang, Y. J.

AU - Park, S.

AU - Kim, B. K.

AU - Kim, N. K.

PY - 2009/2/3

Y1 - 2009/2/3

N2 - Background: Many patients with extranodal natural killer/T-cell lymphoma (NTCL) fail to the front-line therapy and need an effective second-line chemotherapy. Patients and methods: This was single-institutional, phase II study. The primary end point was response rate and secondary end points were toxicity, time to treatment failure (TTF), and overall survival (OS). Patients with relapsed or refractory NTCL were eligible. They received the chemotherapy consisting of ifosfamide, methotrexate, etoposide, and prednisolone and it was repeated every 3 weeks. Results: Thirty-two patients were enrolled and 15 patients had achieved partial remission (PR) or complete remission (CR) after the front-line chemotherapy. The International Prognostic Index scores were 0-1 in thirteen, 2 in five, 3 in five, and 4-5 in nine patients. Twelve and two patients achieved CR and PR, respectively. Median OS and TTF of all patients were 8.2 and 3.7 months, respectively. Non-hematologic toxic effects were well tolerated, but grade 3/4 leukopenia occurred in 11.7% of all cycles. Four patients developed febrile neutropenia and one patient died due to pneumonia. Conclusions: This chemotherapy regimen was moderately effective for relapsed/refractory extranodal NTCL, nasal type. Toxic effects were moderate, but caution should be exercised to prevent severe infection.

AB - Background: Many patients with extranodal natural killer/T-cell lymphoma (NTCL) fail to the front-line therapy and need an effective second-line chemotherapy. Patients and methods: This was single-institutional, phase II study. The primary end point was response rate and secondary end points were toxicity, time to treatment failure (TTF), and overall survival (OS). Patients with relapsed or refractory NTCL were eligible. They received the chemotherapy consisting of ifosfamide, methotrexate, etoposide, and prednisolone and it was repeated every 3 weeks. Results: Thirty-two patients were enrolled and 15 patients had achieved partial remission (PR) or complete remission (CR) after the front-line chemotherapy. The International Prognostic Index scores were 0-1 in thirteen, 2 in five, 3 in five, and 4-5 in nine patients. Twelve and two patients achieved CR and PR, respectively. Median OS and TTF of all patients were 8.2 and 3.7 months, respectively. Non-hematologic toxic effects were well tolerated, but grade 3/4 leukopenia occurred in 11.7% of all cycles. Four patients developed febrile neutropenia and one patient died due to pneumonia. Conclusions: This chemotherapy regimen was moderately effective for relapsed/refractory extranodal NTCL, nasal type. Toxic effects were moderate, but caution should be exercised to prevent severe infection.

KW - NK/T-cell lymphoma

KW - Salvage chemotherapy

KW - Second-line chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=58949083841&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58949083841&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdn551

DO - 10.1093/annonc/mdn551

M3 - Article

VL - 20

SP - 121

EP - 128

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 1

ER -